Linfomas
Hutchings, M, Zelenetz, A, Christensen, JH, Hernandez, AC, Assouline, S, Castillo, LEM, Kothari, S, Modi, D, Albendea, MAC, Cubillas, D, Garcia-Sancho, AM, Diefenbach, CM, Kuruvilla, J, Caimi, PF, Patel, K, Landrette, S, Zhi, ER, Zhang, YY, Meier, R, Matasar, MJ
"Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL)".
Cancer Res.. 86(8): CT268. 2026. [doi:10.1158/1538-7445.AM2026-CT268]
Huerga-Domínguez, S, Ariceta, B, Aguirre-Ruiz, P, San Martín-Uriz, P, Sarvide, S, López-Janeiro, A, Alignani, D, López, A, Ezponda, T, Figueroa, R, Grande, C, Alfonso, A, Pena, E, Browne, S, Robledano, R, Vilas-Zornoza, A, Roa, S, Martínez-Climent, JA, Prósper, F, Canales, M
"Integrated Single-Cell and Spatial Multi-Omics of Clonal Precursors and Immune Niches in Germinal Center Lymphomas".
Cancers. 18(7): 1122. 2026. [doi:10.3390/cancers18071122]
Panizo-Inogés, M, Marcos-Jubilar, M, González-Porras, JR, Puerta-Vazquez, C, Fernández-Arias, C, Rodríguez-Otero, P, Alfonso-Pierola, A, Villar, S, Canales, MA, Orbe, J, Páramo, JA, Prósper, F, Lecumberri, R
"Haemostatic changes during CART cell therapy and risk of complications".
Cancer Immunol. Immunother.. 75(4): 130. 2026. [doi:10.1007/s00262-026-04371-6]
Iacoboni, G, Kyvsgaard, ER, Garces, VN, Russler-Germain, DA, Lewis, K, Garcia-Sancho, AM, Carro, I, Thompson, PA, Therwhanger, D, Quintela, D, Ku, M, Gomez, P, Valencia, E, Vega, G, Jimenez-Ubieto, A, Bastos-Oreiro, M, Serna, A, Husby, S, De La Cruz, B, Luan, J, Camarillas, S, Medina, L, Cabero, A, Cordoba, R, Canales, M, Sancho, JM, Bosch, F, Sureda, A, Schuster, S, Cheah, CY, Hutchings, M, Barba, P, Abrisqueta, P
"Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma".
Blood Adv.. 10(6): 1947 - 1951. 2026. [doi:10.1182/bloodadvances.2025018546]
Jelinek T, Žihala D, Zabaleta A, Kostopoulos IV, Soucek O, Venglar O, Moreno C, Fotiou D, Radova E, Tamariz-Amador LE, Theodorakakou F, Muronova L, Manubens A, Tsitsilonis O, Popková T, Gonzalez C, Anilkumar Sithara A, Corrado F, Bidikian N, Guerrero C, Kapustova V, Bilek D, Hagner PR, Larrayoz M, Martínez-Climent JA, Broskevicová L, Mihalyova J, Merz M, Sevcikova T, Ghobrial IM, San-Miguel JF, Dimopoulos MA, Rodriguez-Otero P, Radocha J, Kastritis E, Paiva B, Hajek R
"Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs.".
Blood. 147(10). 2026. [doi:10.1182/blood.2025029572]
Meler, A, Gusi-Vives, M, De Barrios, O, Azagra, A, Collazo, O, Melchor, J, Del Monte-Monge, A, Gyorffy, B, Verdu-Bou, M, Navarro, JT, Martín-Subero, JI, Roué, G, Ramiro, AR, Roa, S, Parra, M
"HDAC7 is a key factor for the germinal center reaction and its underexpression is associated with DLBCL prognosis".
J. Immunol.. 215(3): vkag015. 2026. [doi:10.1093/jimmun/vkag015]
Bjorklund CC, Larrayoz M, Kang J, Chiu H, Shtraizent N, Wu L, Li S, Hsu CC, Zhao J, Amatangelo M, Chow TT, Wollerman K, Singh RK, Sridhara S, Dudhgaonkar S, Subramanyam P, Ghosh K, Richardson PG, Bahlis NJ, Thakurta A, Martinez-Climent JA, Gandhi AK, Hagner PR
"Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma.".
Blood Neoplasia. 3(1): 100179 - 100179. 2026. [doi:10.1016/j.bneo.2025.100179]
Navarro, F, Lozano, T, Fuentes-Garcia, A, Sánchez-Moreno, I, Larrayoz, M, Justicia, P, Perucha, B, Martinez-Tabar, M, Martinez-Turrillas, R, Casares, N, Martín-Otal, C, Gorraiz, M, Meermeier, EW, Chesi, M, Lake, D, Bergsagel, PL, Santamaría, E, Calleja-Cervantes, ME, San Martín-Uriz, P, Jordana-Urriza, L, Agirre, X, Hervás-Stubbs, S, Rodriguez-Madoz, JR, Martinez-Climent, JA, Prosper, F, Lasarte, JJ
"Reprogramming glutamine metabolism enhances BCMA-CAR T-cell fitness and therapeutic efficacy in multiple myeloma".
Blood. 146(24): 2931 - 2944. 2025. [doi:10.1182/blood.2024027496]
Maura F, Freeman CL, Maclachlan KH, Ilundain ML, Ziccheddu B, Meermeier EW, Garces JJ, Durante M, Lee H, Firestone R, Menges M, Reid K, Diamond B, Papadimitriou M, Silva AS, Sudalagunta PR, Leblay N, Ahn S, Fuller E, Briercheck E, Sharik ME, Du MT, Agius P, Hansen DK, Song X, Zhao X, Meads MB, Teer J, Jelinek T, Hagner P, Baz R, Alsina M, Ramasubramanian AM, Smith E, Giralt SA, Mailankody S, Bergsagel LP, Neri P, Chesi M, Martinez-Climent JA, Locke FL, Bahlis NJ, Landgren O, Hamadeh I, Usmani SZ, Shain KH
"Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.".
bioRxiv. . 2025. [doi:10.64898/2025.12.08.692978]
Martin-Sanchez, E, Lasa, M, Garces, JJ, Bertamini, L, Kostopoulos, I, D'Agostino, M, Zihala, D, Weinhold, N, Roccaro, A, Corre, J, Gracia, H, Termini, R, Manrique, I, Vicente, C, Jimenez, M, Balari, AS, Prosper, F, Ocio, E, Garzón, S, García, EG, Cabezudo, E, Oriol, A, Lakhwani, S, Pérez-Montaña, A, Espinosa, MC, Sonneveld, P, Terpos, E, Gay, F, Jelinek, T, Larrayoz, M, Martinez-Climent, JA, Dachs, LR, Creixenti, JBB, Mateos, MV, Martinez-Lopez, J, Palacios, JJL, San-Miguel, J, Romero, MTC, Puig, N, Paiva, B
"Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features".
Blood. 146: 366 - 367. 2025. [doi:10.1182/blood-2025-366]
|